^
    3d
    Phase I clinical study evaluating the safety, tolerability, pharmacokinetic characteristics, and preliminary efficacy of LNF1901 in the treatment of advanced malignant tumor patients (ChiCTR2500111722)
    P1, N=82, Recruiting, Sun Yat-sen University Cancer Center; Sun Yat-sen University Cancer Center
    New P1 trial
    5d
    Personalized Peptide Vaccine in Treating Patients With Advanced Pancreatic Cancer or Colorectal Cancer (clinicaltrials.gov)
    P1, N=117, Active, not recruiting, M.D. Anderson Cancer Center | Enrolling by invitation --> Active, not recruiting
    Enrollment closed
    |
    CA 19-9 (Cancer antigen 19-9)
    |
    Keytruda (pembrolizumab) • Zyclara (imiquimod) • sotigalimab (PYX-107)
    6d
    A Study of KK2269 in Adult Participants With Solid Tumors (clinicaltrials.gov)
    P1, N=101, Recruiting, Kyowa Kirin Co., Ltd. | N=71 --> 101 | Trial completion date: Dec 2027 --> Mar 2029 | Trial primary completion date: Dec 2027 --> Mar 2029
    Enrollment change • Trial completion date • Trial primary completion date • First-in-human
    |
    docetaxel
    13d
    CAR-T triggers TAM reeducation and adaptive anti-tumor response via TREM2 deficiency or CD40 agonist. (PubMed, Cell Rep Med)
    Notably, the clinical agonist sotigalimab similarly enhances human CD8+ T cell migration in vitro. Our findings highlight the significance of combining GPC3-CAR-T therapy with CD40 agonist as a critical pre-requisite for eliciting reeducation of TAMs and enhancing the efficacy of CAR-T therapy in HCC.
    Journal • IO biomarker
    |
    CD8 (cluster of differentiation 8) • CXCL9 (Chemokine (C-X-C motif) ligand 9) • STAT1 (Signal Transducer And Activator Of Transcription 1) • CD40 (CD40 Molecule) • TREM2 (Triggering Receptor Expressed On Myeloid Cells 2)
    |
    sotigalimab (PYX-107)
    21d
    FORTRESS: NG-350A Plus Chemoradiotherapy for Locally Advanced Rectal Cancer (clinicaltrials.gov)
    P1, N=30, Recruiting, Akamis Bio | Trial completion date: May 2028 --> Nov 2028 | Trial primary completion date: May 2026 --> Nov 2026
    Trial completion date • Trial primary completion date
    |
    capecitabine • NG-350A
    25d
    TACTIC: MP0317 in Combination With Chemoimmunotherapy in First Line Treatment for Patients With Advanced Biliary Tract Carcinoma (clinicaltrials.gov)
    P2, N=75, Recruiting, Centre Hospitalier Universitaire de Besancon | Not yet recruiting --> Recruiting | Trial completion date: Jun 2029 --> Nov 2029 | Initiation date: Jun 2025 --> Dec 2025 | Trial primary completion date: Jun 2028 --> Nov 2028
    Enrollment open • Trial completion date • Trial initiation date • Trial primary completion date
    |
    cisplatin • Imfinzi (durvalumab) • gemcitabine • MP0317
    25d
    A Study of ABBV-927 and ABBV-181, an Immunotherapy, in Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=163, Active, not recruiting, AbbVie | Trial completion date: Mar 2026 --> Sep 2026 | Trial primary completion date: Mar 2026 --> Sep 2026
    Trial completion date • Trial primary completion date
    |
    budigalimab (ABBV-181) • giloralimab (ABBV-927)
    27d
    Phase I(b) study evaluating the safety and efficacy of intratumoral agonistic anti-CD40 (selicrelumab) in combination with anti-PD-L1 (atezolizumab) in patients with refractory or relapsed B-cell lymphoma (ITSELF trial). (PubMed, Immunooncol Technol)
    The trial was stopped prematurely because of issues with selicrelumab drug supply. The combination of 1 mg of intratumoral selicrelumab and 1200 mg of intravenous atezolizumab was safe for patients with relapsed/refractory B-cell lymphoma and led to some tumor stabilization or regression, although it did not result in objective tumor response.
    Journal
    |
    PD-1 (Programmed cell death 1)
    |
    Tecentriq (atezolizumab) • selicrelumab (RG7876)
    27d
    1B-22-2: In Situ Immunomodulation With CDX-301, Radiation Therapy, CDX-1140 and Poly-ICLC in Patients w/ Unresectable and Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=14, Active, not recruiting, University of Southern California | Recruiting --> Active, not recruiting | Trial completion date: Jan 2027 --> Jan 2028 | Trial primary completion date: Jan 2026 --> Jan 2027
    Enrollment closed • Trial completion date • Trial primary completion date • IO biomarker
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1)
    |
    Keytruda (pembrolizumab) • CDX-1140 • Hiltonol (poly-ICLC) • Mobista (CDX-301)
    28d
    A Safety Trial of GEN1042 in Japanese Subjects With Malignant Solid Tumors (clinicaltrials.gov)
    P1, N=42, Active, not recruiting, Genmab | Trial primary completion date: Mar 2026 --> Nov 2026
    Trial primary completion date
    |
    Keytruda (pembrolizumab) • cisplatin • carboplatin • 5-fluorouracil • tecaginlimab (GEN1042)
    28d
    Window Study of Intratumoral Mitazalimab in Breast Cancer (WINIT-BC) (clinicaltrials.gov)
    P1, N=32, Not yet recruiting, Jennifer Zhang
    New P1 trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
    |
    Opdivo (nivolumab) • mitazalimab (ADC-1013)
    1m
    A Study of SHR-7367 With Anti-tumor Agents in Patients With Solid Tumors (clinicaltrials.gov)
    P1/2, N=100, Recruiting, Shanghai Hengrui Pharmaceutical Co., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    gemcitabine • paclitaxel • AiRuiLi (adebrelimab) • SHR-7367